The phase II SAVANNAH trial evaluated osimertinib plus savolitinib, a highly selective MET TKI, versus savolitinib monotherapy in patients with MET-amplified or overexpressed tumors following first-line osimertinib, as defined by MET IHC3+/≥90% (3+ staining intensity in ≥90% of tumor cells) and/or FISH10+ (≥10 MET gene copies) status (39). The gene discussed is MET; the disease is neoplasm.